Should We Increase GFR with Bardoxolone in Alport Syndrome? - Wikidata - wikimedia - TriplyDB

Should We Increase GFR with Bardoxolone in Alport Syndrome?

Should We Increase GFR with Bardoxolone in Alport Syndrome?

http://www.wikidata.org/entity/Q49680628

about

Editorial Note: From Both Sides Now.Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).

P2860

Q49680595-5CAD1CA8-A694-47A4-9E66-5717980D82A3 Q55476982-44FF807A-C959-4F6B-B0B8-A4B6B4403A3A

P2860

Should We Increase GFR with Bardoxolone in Alport Syndrome?

http://www.wikidata.org/entity/Q49680628

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Should We Increase GFR with Bardoxolone in Alport Syndrome?

@en

Should We Increase GFR with Bardoxolone in Alport Syndrome?

@nl

type

label

Should We Increase GFR with Bardoxolone in Alport Syndrome?

@en

Should We Increase GFR with Bardoxolone in Alport Syndrome?

@nl

prefLabel

Should We Increase GFR with Bardoxolone in Alport Syndrome?

@en

Should We Increase GFR with Bardoxolone in Alport Syndrome?

@nl

P1433

Q49680628-DF6271C1-18D4-42CD-9D9A-0E22DFDA8D1D

P1476

Q49680628-8DE62D1F-8FD4-4716-87C6-2097F1F25E44

P2093

Q49680628-FE32D73E-C609-48DC-AFBB-3C4460C029ED

P2860

Q49680628-2CF3091A-79DE-4334-86B2-18FF6BEE9E9B

Q49680628-7BE70704-0662-468F-ACBC-798CE257C2ED

Q49680628-9C9928A2-2EF9-48CC-81E4-94B8742431B5

Q49680628-9F7F0A3D-93E7-47FD-91A8-160E39BE1BC8

Q49680628-CCDF33FC-465D-450E-9B81-D2F68EB35FB2

Q49680628-E7A22F4D-CE2D-4733-AD54-712E4EEEC572

Q49680628-FEF36BA0-A868-4FEE-8919-59BCF8660A5D

P304

Q49680628-822CBD5E-2AEB-498B-B0D1-C2A2DCFC2AB8

P31

Q49680628-C87A579A-AA31-4357-AFF7-E6D9FCE69E3C

P356

Q49680628-191664AC-3AF0-43A8-B876-1075F7D2934C

P433

Q49680628-AF25ED5A-E3CF-4529-9CD5-E36862BAC398

P478

Q49680628-F6286D39-5D54-4734-92DF-89CEC71D04E8

P50

Q49680628-60474751-5983-43DC-85CA-6D8BF3EE85A9

P577

Q49680628-DD70704D-C475-453C-AA3B-E8E9C4B59C66

P698

Q49680628-F87EEC8B-CDE9-4E7F-93A3-F33273E99F57

P932

Q49680628-6A42353B-0205-4EA8-8BA3-94C0CDFE6C51

P356

P1433

Journal of the American Society of Nephrology

P1476

Should We Increase GFR with Bardoxolone in Alport Syndrome?

@en

P2093

Colin Baigent

http://www.w3.org/2001/XMLSchema#string

P2860

Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts.

Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.

P304

357-359

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2017101062

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29371420

http://www.w3.org/2001/XMLSchema#string

P932

5791073

http://www.w3.org/2001/XMLSchema#string